TheraRadar
← Back
Data updated: Jun 12, 2026

PHARMATON

Specialty

PHARMATON is a specialty pharmaceutical company focused on Neurology.

1977
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

PHARMATON's Key Drugs

PHARMATON's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHARMATON's Recent FDA Approvals

New NDA/BLA approvals for PHARMATON over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHARMATON's Therapeutic Areas

PHARMATON's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
1 drugs

PHARMATON's Top Competitors

PHARMATON's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PHARMATON Pipeline Snapshot

Active clinical trials for PHARMATON across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling